Optimal Stenting Strategy For True Bifurcation Lesions (PERFECT)
Primary Purpose
Coronary Artery Disease
Status
Completed
Phase
Phase 4
Locations
Korea, Republic of
Study Type
Interventional
Intervention
Crush technique
provisional T stenting
Sponsored by

About this trial
This is an interventional treatment trial for Coronary Artery Disease focused on measuring stent, bifurcation, coronary artery stenosis, balloon angioplasty
Eligibility Criteria
Inclusion Criteria:
Clinical
- Patients with angina and documented ischemia or patients with documented silent ischemia
- Patients who are eligible for intracoronary stenting
- Age >18 years, <75 ages
Angiographic
- De novo lesion located in a major bifurcation point with the MEDINA classification type 1.1.0, 1.0.0, or 0.1.0
- Main vessel : >= 2.5 mm in vessel size, >= 50% in diameter stenosis and =< 50 mm in lesion length by visual estimation, in which the lesion seems to be covered with =< 2 stents
- Side branch : >= 2.0 mm in vessel size, >= 50% in diameter stenosis, and < 20 mm in lesion length by visual estimation, in which the lesion seems to be covered with single stent
Exclusion Criteria:
- History of bleeding diathesis or coagulopathy
- Pregnant
- Known hypersensitivity or contra-indication to contrast agent, heparin, sirolimus and paclitaxel
- Limited life-expectancy (less than 1 year) due to combined serious disease
- ST-elevation acute myocardial infarction < 2 weeks
Characteristics of lesion:
- Left main disease
- In-stent restenosis
- Graft vessels
- Chronic total occlusion
- TIMI flow =< grade 2 in the side branch
- Renal dysfunction, creatinine >= 2.0mg/dL
- Contraindication to aspirin, clopidogrel or cilostazol
- LV ejection fraction =< 35%
Sites / Locations
- Soonchunhyang University Bucheon Hospital
- Busan Saint Mary's Hospital
- Cheongju Saint Mary's Hospital
- Kangwon University Hospital
- Chungnam National University Hospital
- Kyungsang University Hospital
- Hallym University Sacred Heart Hospital
- Catholic University, Kangnam St. Mary's Hospital
- Hallym University Sacred Heart Hospital
- Korea Veterans Hospital
- Aju University Hospital
- Ulsan University Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
bifurcation stent technique
bifurcation stent techniqe
Arm Description
crush technique
provisional T stenting
Outcomes
Primary Outcome Measures
Angiographic binary restenosis rate (diameter stenosis >= 50%) at 8 months in either main or side branch
Secondary Outcome Measures
Composite of major cardiac adverse events (MACE) including death, MI, stent thrombosis and ischemia-driven target vessel revascularization
Reocclusion rate at the side branch at 8 month angiographic follow-up
Late loss at the main vessel and the side branch
Restenosis rate at the main vessel and/or side branch
Influence of bifurcation angle
Influence of new three segment bifurcation QCA software
Fluoroscopic time
Procedure time
Amount of contrast agent
Number of used stents
FFR assessment in the side branch
Full Information
NCT ID
NCT00693251
First Posted
June 5, 2008
Last Updated
November 16, 2015
Sponsor
Seung-Jung Park
Collaborators
CardioVascular Research Foundation, Korea
1. Study Identification
Unique Protocol Identification Number
NCT00693251
Brief Title
Optimal Stenting Strategy For True Bifurcation Lesions
Acronym
PERFECT
Official Title
Phase IV Study of Optimal Stenting Strategy For True Bifurcation Lesions
Study Type
Interventional
2. Study Status
Record Verification Date
November 2015
Overall Recruitment Status
Completed
Study Start Date
January 2008 (undefined)
Primary Completion Date
June 2015 (Actual)
Study Completion Date
June 2015 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Seung-Jung Park
Collaborators
CardioVascular Research Foundation, Korea
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
It is unclear which stenting strategy will be optimal for true bifurcation coronary lesions.
Detailed Description
The outcome of percutaneous coronary intervention of bifurcation lesions with bare-metal stents is hindered by increased rates of procedural complications and long-term major adverse cardiac events compared with non-bifurcated lesions.1 Randomized studies have demonstrated that drug-eluting stents reduce restenosis when used in relatively simple lesions; and recent data have demonstrated efficacy of the sirolimus-eluting stent for bifurcation lesions compared with historical data of BMS. In one study of bifurcation lesions, the overall restenosis rate was 23%, with the majority of side branch restenoses occurring at the ostium after use of a T-stenting technique. Indeed, side branch restenosis occurred in 16.7% after T-stenting, compared with 7.1% after other stenting techniques.
The "crush" technique of bifurcation stenting with DESs was introduced by Colombo et al. in 2003 as a relatively simple technique that ensures complete coverage of the side branch ostium, thereby facilitating drug delivery at this site. Initial data of 20 patients treated with this technique with SES suggest that it is a safe method, with an acceptable rate of procedural complications and no further adverse events up to 30 days follow-up. Recently, angiographic data have shown the importance of simultaneous kissing balloon post-dilation in reducing restenosis and need for target lesion revascularization. They also reported that compared to T-stenting, crushing with final kissing balloon dilatation was associated with lower rate of restenosis and target lesion revascularization. Consequently, the crushing is currently most promising technique in treating bifurcation lesions using two stents. However, despite the advance of bifurcation stenting technique, the superiority of bifurcation stenting with crushing technique over simple stenting in bifurcation lesion has not been demonstrated.
Therefore, we conducted the prospective randomized study comparing crushing technique with final kissing balloon dilatation and a simple technique (main vessel stenting and provisional T-stenting) for treatment of true bifurcation lesions.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Coronary Artery Disease
Keywords
stent, bifurcation, coronary artery stenosis, balloon angioplasty
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
420 (Actual)
8. Arms, Groups, and Interventions
Arm Title
bifurcation stent technique
Arm Type
Experimental
Arm Description
crush technique
Arm Title
bifurcation stent techniqe
Arm Type
Active Comparator
Arm Description
provisional T stenting
Intervention Type
Procedure
Intervention Name(s)
Crush technique
Other Intervention Name(s)
Sirolimus, Paclitaxel, Zotarolimus and Everolimus stents
Intervention Description
Crush technique
Intervention Type
Procedure
Intervention Name(s)
provisional T stenting
Other Intervention Name(s)
Sirolimus, Paclitaxel, Zotarolimus and Everolimus stents
Intervention Description
Provisional T stenting
Primary Outcome Measure Information:
Title
Angiographic binary restenosis rate (diameter stenosis >= 50%) at 8 months in either main or side branch
Time Frame
8 months
Secondary Outcome Measure Information:
Title
Composite of major cardiac adverse events (MACE) including death, MI, stent thrombosis and ischemia-driven target vessel revascularization
Time Frame
2 years
Title
Reocclusion rate at the side branch at 8 month angiographic follow-up
Time Frame
8 months
Title
Late loss at the main vessel and the side branch
Time Frame
8 months
Title
Restenosis rate at the main vessel and/or side branch
Time Frame
8 months
Title
Influence of bifurcation angle
Time Frame
8 months
Title
Influence of new three segment bifurcation QCA software
Time Frame
8 months
Title
Fluoroscopic time
Time Frame
baseline
Title
Procedure time
Time Frame
baseline
Title
Amount of contrast agent
Time Frame
baseline
Title
Number of used stents
Time Frame
baseline
Title
FFR assessment in the side branch
Time Frame
baseline and 8 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Clinical
Patients with angina and documented ischemia or patients with documented silent ischemia
Patients who are eligible for intracoronary stenting
Age >18 years, <75 ages
Angiographic
De novo lesion located in a major bifurcation point with the MEDINA classification type 1.1.0, 1.0.0, or 0.1.0
Main vessel : >= 2.5 mm in vessel size, >= 50% in diameter stenosis and =< 50 mm in lesion length by visual estimation, in which the lesion seems to be covered with =< 2 stents
Side branch : >= 2.0 mm in vessel size, >= 50% in diameter stenosis, and < 20 mm in lesion length by visual estimation, in which the lesion seems to be covered with single stent
Exclusion Criteria:
History of bleeding diathesis or coagulopathy
Pregnant
Known hypersensitivity or contra-indication to contrast agent, heparin, sirolimus and paclitaxel
Limited life-expectancy (less than 1 year) due to combined serious disease
ST-elevation acute myocardial infarction < 2 weeks
Characteristics of lesion:
Left main disease
In-stent restenosis
Graft vessels
Chronic total occlusion
TIMI flow =< grade 2 in the side branch
Renal dysfunction, creatinine >= 2.0mg/dL
Contraindication to aspirin, clopidogrel or cilostazol
LV ejection fraction =< 35%
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Seung-Jung Park, MD, PhD
Organizational Affiliation
Asan Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Soonchunhyang University Bucheon Hospital
City
Bucheon
Country
Korea, Republic of
Facility Name
Busan Saint Mary's Hospital
City
Busan
Country
Korea, Republic of
Facility Name
Cheongju Saint Mary's Hospital
City
Cheongju
Country
Korea, Republic of
Facility Name
Kangwon University Hospital
City
Chuncheon
Country
Korea, Republic of
Facility Name
Chungnam National University Hospital
City
Daejeon
Country
Korea, Republic of
Facility Name
Kyungsang University Hospital
City
Jinju
Country
Korea, Republic of
Facility Name
Hallym University Sacred Heart Hospital
City
PyeongChon
Country
Korea, Republic of
Facility Name
Catholic University, Kangnam St. Mary's Hospital
City
Seoul
Country
Korea, Republic of
Facility Name
Hallym University Sacred Heart Hospital
City
Seoul
Country
Korea, Republic of
Facility Name
Korea Veterans Hospital
City
Seoul
Country
Korea, Republic of
Facility Name
Aju University Hospital
City
Suwon
Country
Korea, Republic of
Facility Name
Ulsan University Hospital
City
Ulsan
Country
Korea, Republic of
12. IPD Sharing Statement
Learn more about this trial
Optimal Stenting Strategy For True Bifurcation Lesions
We'll reach out to this number within 24 hrs